Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Increasing duration of tamoxifen therapy improves survival in women with breast cancer but the impact of adherence to tamoxifen on mortality is unclear. This study investigated whether women prescribed tamoxifen after surgery for breast cancer adhered to their prescription and whether adherence influenced survival. A retrospective cohort study of all women with incident breast cancer in the Tayside region of Scotland between 1993 and 2002 was linked to encashed prescription records to calculate adherence to tamoxifen. Survival analysis was used to determine the effect of adherence on all-cause mortality. In all 2080 patients formed the study cohort with 1633 (79%) prescribed tamoxifen. The median duration of use was 2.42 years (IQR=1.04-4.89 years). Longer duration was associated with better survival but this varied over time. The hazard ratio for mortality in relation to duration at 2.4 years was 0.85, 95% CI=0.83-0.87. Median adherence to tamoxifen was 93% (interquartile range=84-100%). Adherence <80% was associated with poorer survival, hazard ratio 1.10, 95% CI=1.001-1.21. Persistence with tamoxifen was modest with only 49% continuing therapy for 5 years of those followed up for 5 years or more. Increased duration of tamoxifen reduces the risk of death, although one in two women do not complete the recommended 5-year course of treatment. A significant proportion of women have low adherence to tamoxifen and are at increased risk of death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Women with breast cancer who do not adhere to adjuvant endocrine therapy (AET) have increased risks of mortality and recurrence.”
From Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: Protocol for a pilot fractional factorial trial (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Low adherence and early cessation of AET are associated with an increased risk of breast cancer recurrence and all-cause mortality [5–12].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and is linked with an increased risk of cancer-specific and all-cause mortality [5–12].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“a Scottish study which observed a 10% higher risk of death (hazard ratio=1.10, 95% CI: 1.001–1.21) associated with adherence to tamoxifen of under 80%, (McCowan et al, 2008)”
From Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain (2012) · cites this paper as McCowan et al, 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 1×
“A Charlson’s co-morbidity index, which included a category for presence of cancer, was derived for each patient using standard procedures and the ICD codes version 9 (Deyo et al, 1992) and 10 (Sundararajan et al, 2004) in the hospital admission records.”
MethodOsterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality
Sundararajan, V., Henderson, T., Perry, C., Muggivan, A., Quan, H., & Ghali, W. A. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.03.012 · Cited by 2,439 · cited 1×
“A Charlson’s co-morbidity index, which included a category for presence of cancer, was derived for each patient using standard procedures and the ICD codes version 9 (Deyo et al, 1992) and 10 (Sundararajan et al, 2004) in the hospital admission records.”
MethodDiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169 · cited 1×
“The level of non-adherence reported by studies is large, up to 50%, and many studies have shown worse clinical outcomes associated with low adherence (DiMatteo, 2004).”
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320 · cited 2×
“Tamoxifen is an important adjuvant therapy for patients with breast cancer (Osborne, 1998) and reduces the breast cancer mortality rate over 15 years by 31% in women with oestrogen receptor-positive early breast cancers.”
BackgroundFisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., Cronin, W. M., & Contributors, O. N. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.527 · Cited by 1,268 · cited 1×
“Adherence to adjuvant tamoxifen during clinical trials is high, with reported levels of 94–100% (Fisher et al, 1994, 1996; Dewar et al, 1996).”
BackgroundInterventions to Enhance Patient Adherence to Medication Prescriptions: Scientific Review
McDonald, H. P., Garg, A. X., & Haynes, R. B. (2002) · JAMA · doi:10.1001/jama.288.22.2868 · Cited by 1,176 · cited 1×
“Adherence to a prescribed medication can be defined as: ‘the extent to which a patient’s behaviour y coincides with medical or health advice’ (McDonald et al, 2002).”
BackgroundDeprivation and Health in Scotland
Tunstall-Pedoe, H. (1993) · Postgraduate Medical Journal · doi:10.1136/pgmj.69.814.665-a · Cited by 1,167
Survival Analysis Part I: Basic concepts and first analyses
Clark, T. G., Bradburn, M. J., Love, S. B., & Altman, D. G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601118 · Cited by 1,030 · cited 2×
“Lastly, the outcome used within the study was all-cause mortality selected as the accurate recording of cause of death has been questioned in the literature (Clark et al, 2003).”
MethodFisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 861 · cited 2×
“Adherence to adjuvant tamoxifen during clinical trials is high, with reported levels of 94–100% (Fisher et al, 1994, 1996; Dewar et al, 1996).”
BackgroundNonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676 · cited 5×
“The study was granted approval from the Tayside Committee on Medical Research Ethics and the Caldicott Guardian.”
BackgroundMethodResultInfluentialFisher, B., Dignam, J., Bryant, J., & Wolmark, N. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.684 · Cited by 635 · cited 1×
“The first, duration of tamoxifen therapy has an effect on disease recurrence and mortality from breast cancer with 5 years being the recommended treatment period (Swedish Breast Cancer Cooperative Group, 1996; Fisher et al, 2001; Yood et al, 2008).”
BackgroundDeprivation and health in Scotland.
Carstairs, V., & Morris, R. (1990) · PubMed · Cited by 434
Bradburn, M. J., Clark, T. G., Love, S. B., & Altman, D. G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601120 · Cited by 390
Owusu, C., Buist, D. S. M., Field, T. S., Lash, T. L., Thwin, S. S., Geiger, A. M., Quinn, V. P., Frost, F., Prout, M., Yood, M. U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1022 · Cited by 304 · cited 2×
“1766 British Journal of Cancer (2008) 99(11), 1763 – 1768 & 2008 Cancer Research UK C lin ic a l S tu d ie s level and was similar to the figure reported by Fink et al (2004) at 2 years and Owusu et al (2008) at 5 years.”
BackgroundResultAdjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
Demissie, S., Silliman, R. A., & Lash, T. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.322 · Cited by 300 · cited 3×
“All statistical analyses were performed using Stata version 9.”
BackgroundMethodWei, L., Wang, J., Thompson, P., Wong, S., Struthers, A. D., & MacDonald, T. M. (2002) · Heart · doi:10.1136/heart.88.3.229 · Cited by 292
Fink, A. K., Gurwitz, J., Rakowski, W., Guadagnoli, E., & Silliman, R. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.064 · Cited by 281 · cited 3×
“1766 British Journal of Cancer (2008) 99(11), 1763 – 1768 & 2008 Cancer Research UK C lin ic a l S tu d ie s level and was similar to the figure reported by Fink et al (2004) at 2 years and Owusu et al (2008) at 5 years.”
ResultEarly discontinuation of tamoxifen: A Lesson for oncologists
Barron, T. I., Connolly, R., Bennett, K., Feely, J., & Kennedy, M. J. (2007) · Cancer · doi:10.1002/cncr.22485 · Cited by 279 · cited 3×
“Non-persistence with tamoxifen therapy at 1 year differed from the figure reported in the study by Barron et al (2007) but at three and a half years was at a similar Table 2 Clinical and pathological characteristics of cancer at initial diagnosis Patients with tamoxifen (”
BackgroundMethodResultInfluentialSwedish Breast Cancer Cooperative Group (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1543 · Cited by 261
Adherence to endocrine therapy for breast cancer
Chlebowski, R. T., & Geller, M. L. (2006) · Oncology · doi:10.1159/000100444 · Cited by 251 · cited 1×
“The study was granted approval from the Tayside Committee on Medical Research Ethics and the Caldicott Guardian.”
Adherence beliefs among breast cancer patients taking tamoxifen
Grunfeld, E. A., Hunter, M. S., Sikka, P., & Mittal, S. (2005) · Patient Education and Counseling · doi:10.1016/j.pec.2004.10.005 · Cited by 245 · cited 2×
“Other work agrees with this finding and also suggests side effects or a perception of low benefits from taking medication leads to lower adherence in younger women (Fink et al, 2004; Grunfeld et al, 2005; Chlebowski et al, 2006).”
ResultPrimary Care for Survivors of Breast Cancer
Burstein, H. J., & Winer, E. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010123431506 · Cited by 241 · cited 1×
“(Early Breast Cancer Trialists’ Collaborative, 2005) Tamoxifen (20 mg once daily) is recommended for patients for 5 years adjuvant therapy (Early Breast Cancer Trialists’ Collaborative Group, 2004) to provide maximum benefit (Fisher et al, 1996; Stewart et al, 1996; Burstein and Winer, 2000).”
BackgroundThe Scottish Cancer Trials Breast Group, Stewart, H., Forrest, A., Everington, D., McDonald, C., Dewar, J., Hawkins, R., Prescott, R., & George, W. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.356 · Cited by 177 · cited 1×
“(Early Breast Cancer Trialists’ Collaborative, 2005) Tamoxifen (20 mg once daily) is recommended for patients for 5 years adjuvant therapy (Early Breast Cancer Trialists’ Collaborative Group, 2004) to provide maximum benefit (Fisher et al, 1996; Stewart et al, 1996; Burstein and Winer, 2000).”
BackgroundSelf-citationMortality Impact of Less-than-Standard Therapy in Older Breast Cancer Patients
Yood, M. U., Owusu, C., Buist, D. S. M., Geiger, A. M., Field, T. S., Thwin, S. S., Lash, T. L., Prout, M. N., Wei, F., Quinn, V. P., et al. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.07.015 · Cited by 155 · cited 1×
“The first, duration of tamoxifen therapy has an effect on disease recurrence and mortality from breast cancer with 5 years being the recommended treatment period (Swedish Breast Cancer Cooperative Group, 1996; Fisher et al, 2001; Yood et al, 2008).”
BackgroundPropensity score methods in drug safety studies: practice, strengths and limitations
Wang, J., & Donnan, P. T. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.656 · Cited by 44 · cited 2×
“A propensity score estimating the probability of a patient receiving tamoxifen was calculated using a logistic regression model for age, social class, pathological tumour characteristics, Charlson’s index and co-prescribing (Wang and Donnan, 2001).”
BackgroundMethodSelf-citationMentoring Junior Faculty in Geriatric Oncology: Report From the Cancer and Aging Research Group
Hurria, A., Balducci, L., Naeim, A., Gross, C. P., Mohile, S. G., Klepin, H. D., Tew, W. P., Downey, L., Gajra, A., Owusu, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9771 · Cited by 41
Tamoxifen non-compliance: does it matter?
Murthy, V., Bharia, G., & Sarin, R. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00895-1 · Cited by 35 · cited 5×
“A small survey on self reported adherence in 53 women found that 62% acknowledged having missed at least one dose of tamoxifen in the previous 6 months, with 24% missing at least one dose per week (Murthy et al, 2002).”
BackgroundMethodResultInfluentialTamoxifen compliance in a clinical trial
Dewar, J. A., Stewart, H., & MacDonald, T. M. (1996) · The Breast · doi:10.1016/s0960-9776(96)90060-0 · Cited by 5 · cited 1×
“Adherence to adjuvant tamoxifen during clinical trials is high, with reported levels of 94–100% (Fisher et al, 1994, 1996; Dewar et al, 1996).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group (2004) Tamoxifen for early breast cancer. Cochrane Database of Systematic Reviews, Reviews 2008 Issue 4. John Wiley & Sons, Ltd.: Chichester, UK
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Marital Status and Survival in Patients With Cancer
Aizer, A. A., Chen, M.-H., McCarthy, E. P., Mendu, M. L., Koo, S., Wilhite, T. J., Graham, P. L., Choueiri, T. K., Hoffman, K. E., Martin, N. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6489 · Cited by 1,031
“Investigations relating adherence to outcome in patients with breast, hematologic, and other cancers have yielded similar results.(41-43) The benefits of marriage on all of the outcomes evaluated in this study have additional potential underlying etiologies.”
ResultHershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
“Outside the clinical trial setting, several small observational studies suggest that early discontinuation of hormone therapy is associated with increased mortality; however, these studies were small, single institution and/or had limited follow-up for survival [9, 15, 16].”
BackgroundResultHershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W.-Y., Fehrenbacher, L., Lin Gomez, S., Miles, S., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 828
“ized trials show higher recurrence rates and worse survival with 5 years of treatment.(18,20-23) JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T VOLUME 28 NUMBER 27 SEPTEMBER 20 2010”
Background
Metadata
- Authors
- McCowan, C., Shearer, J., Donnan, P. T., Dewar, J. A., Crilly, M., Thompson, A. M., & Fahey, T. P.
- Affiliations
- University of Dundee (GB)
- University of Aberdeen (GB)
- Royal College of Surgeons in Ireland (IE)
- Corresponding author
- McCowan, C
- Venue
- British Journal of Cancer
- Published
- 2008-11-04
- Volume
- 99
- Issue
- 11
- Pages
- 1763-1768
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2600703
- OpenAlex
- W2139442403
- Semantic Scholar
- c38cb7b39732496842facd7e1ac10daa178005c5
- Cited by
- 343
- References
- 32
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 10 · 2023: 17 · 2022: 22 · 2021: 20 · 2020: 19 · 2019: 20 · 2018: 20 · 2017: 22 · 2016: 20 · 2015: 25 · 2014: 21 · 2013: 32 · 2012: 27
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Funders
- University of Dundee
- NHS Health Scotland
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- tamoxifen, medication adherence, breast cancer, all-cause mortality, survival, treatment persistence, adjuvant endocrine therapy, prescription records
- MeSH terms
- Adult, Aged, Aged, 80 and over, Breast Neoplasms, Female, Humans, Middle Aged, Retrospective Studies, Tamoxifen, Cohort Studies, Drug Monitoring, Chemotherapy, Adjuvant, Selective Estrogen Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
